Increased orexin a concentrations in cerebrospinal fluid of patients with behavioural variant frontotemporal dementia
Open accessAbstract
Orexins are hypothalamic neuropeptides that regulate several physiological functions, such as appetite, arousal, cognition, stress, sleep and metabolism. Emerging pieces of evidence suggest an orexinergic dysfunction in several neuropsychiatric disorders, including depression, anxiety and addiction. A syndromic overlap between behavioural variant frontotemporal dementia (bvFTD) and several psychiatric disorders was recently demonstrated. Therefore, we analysed cerebrospinal fluid (CSF) orexin A concentrations of 40 bvFTD and 32 non-demented patients, correlating neuropeptide concentrations with several clinical characteristics. A significant increase of orexin A concentrations was found in bvFTD patients when compared to controls (p<0.001). CSF orexin A concentration showed a correlation with Mini-Mental State Examination scores, drug assumption, history of compulsive behaviour and extrapyramidal signs. Moreover, we found a relationship between CSF markers of neurodegeneration, total tau and Aβ 1–42 and CSF orexin A concentrations. Our study provides evidence of an orexinergic dysfunction in bvFTD, correlating with several clinical symptoms. Further larger studies are needed to confirm our data.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The neurotransmitter orexin A has been correlated with obsessive-compulsive symptoms (measured by SRI) and extrapyramidal symptoms that may accompany disease progression in bvFTD (cross-sectional, N = 40).
“The neurotransmitter orexin A, known for regulation of various physiological functions (such as appetite and sleep), has been correlated with obsessive-compulsive (measured by SRI) and extrapyramidal symptoms, that may accompany disease progression (cross-sectional, N = 40) (Roveta et al., 2022).”
From The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials (2024) · cites this paper as Roveta et al., 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · see citing works
Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle
Kang, J.-E., Lim, M. M., Bateman, R. J., Lee, J. J., Smyth, L. P., Cirrito, J. R., Fujiki, N., Nishino, S., & Holtzman, D. M. (2009) · Science · doi:10.1126/science.1180962 · Cited by 1,565 · see citing works
Bang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144 · see citing works
Hypocretin (orexin) cell loss in Parkinson's disease
Thannickal, T. C., Lai, Y.-Y., & Siegel, J. M. (2007) · Brain · doi:10.1093/brain/awm097 · Cited by 566 · see citing works
Circadian and sleep disorders in Parkinson's disease
Videnović, A., & Golombek, D. A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.08.018 · Cited by 247 · see citing works
Eating and hypothalamus changes in behavioral‐variant frontotemporal dementia
Piguet, O., Petersén, Å., Lam, B. Y. K., Gabery, S., Murphy, K., Hodges, J. R., & Halliday, G. M. (2010) · Annals of Neurology · doi:10.1002/ana.22244 · Cited by 192 · see citing works
Doherty, C. M., & Forbes, R. B. (2014) · PubMed · Cited by 162 · see citing works
Recent Progress on C‐4‐Modified Podophyllotoxin Analogs as Potent Antitumor Agents
Liu, Y., Tian, J., Qian, K., et al. (2014) · Medicinal Research Reviews · doi:10.1002/med.21319 · Cited by 144 · see citing works
Wienecke, M., Werth, E., Poryazova, R., Baumann‐Vogel, H., Bassetti, C. L., Weller, M., Waldvogel, D., Storch, A., & Baumann, C. R. (2012) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2012.01027.x · Cited by 118 · see citing works
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Han, Y., Yuan, K., Zheng, Y., & Lü, L. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00447-9 · Cited by 116 · see citing works
The Hypocretin/Orexin System: An Increasingly Important Role in Neuropsychiatry
Chen, Q., de Lecea, L., Hu, Z., & Gao, D. (2014) · Medicinal Research Reviews · doi:10.1002/med.21326 · Cited by 84 · see citing works
Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease
Liu, M., Xue, Y., Liu, C., Liu, Y.-H., Diao, H., Wang, Y., Pan, Y.-P., & Chen, L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00835 · Cited by 72 · see citing works
Mena, J. D., Selleck, R. A., & Baldo, B. A. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3323-12.2013 · Cited by 70 · see citing works
CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia
Heywood, W., Hällqvist, J., Heslegrave, A., Zetterberg, H., Fenoglio, C., Scarpini, E. A., Rohrer, J. D., Galimberti, D., & Mills, K. A. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.019 · Cited by 37 · see citing works
Liguori, C., Mercuri, N. B., Nuccetelli, M., Izzi, F., Bernardini, S., & Placidi, F. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180769 · Cited by 37 · see citing works
Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia
Liguori, C., Romigi, A., Mercuri, N. B., Nuccetelli, M., Izzi, F., Albanese, M., Sancesario, G., Martorana, A., Sancesario, G. M., Bernardini, S., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7455-z · Cited by 32 · see citing works
Orexin-A level elevation in recently abstinent male methamphetamine abusers
Chen, W., Kao, C.-F., Chen, P., Lin, S., & Huang, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.02.059 · Cited by 21 · see citing works
A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion
Zibetti, M., Romagnolo, A., Merola, A., Priano, L., Montanaro, E., Angrisano, S., Tribolo, A., Cicolin, A., & Lopiano, L. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8491-2 · Cited by 20 · see citing works
Self-citationTang, H., Zhu, Q., Li, W., Qin, S., Gong, Y., Wang, H., Shioda, S., Li, S., Huang, J., Liu, B., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191029101830 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fieldhouse, J. L. P., van Paassen, D. N., van Engelen, M.-P. E., De Boer, S. C. M., Hartog, W. L., Braak, S., Schoonmade, L. J., Schouws, S. N. T. M., Krudop, W. A., Oudega, M. L., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1382593 · Cited by 8 · see citing works
- Authors
- Roveta, F., Marcinnò, A., Cremascoli, R., Priano, L., Cattaldo, S., Rubino, E., Gallo, E., Boschi, S., Mauro, A., & Rainero, I.
- Affiliations
- IRCCS Istituto Auxologico Italiano (IT)
- University of Turin (IT)
- University of Pavia (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Corresponding author
- Priano, Lorenzo
- ORCID
- Venue
- Neurological Sciences
- Published
- 2021-04-27
- Volume
- 43
- Issue
- 1
- Pages
- 313-317
- ISSN
- 1590-1874 (ISSN-L)
- 1590-3478
- PMC
- PMC8724071
- OpenAlex
- W3158642298
- Cited by
- 6
- References
- 19
- Citations by year
- 2025: 4 · 2024: 2
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Neurological Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Università degli Studi di Torino
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Keywords
- orexin-A, behavioral variant frontotemporal dementia, cerebrospinal fluid biomarkers, neurodegeneration, tau protein, amyloid-beta, compulsive behaviour, extrapyramidal signs, neuropsychiatric symptoms
- MeSH terms
- Orexins, Humans, Case-Control Studies, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
